A recent study by the University of Baylor in the United States shows that the patented turmeric extract of BCM-95 curcumin is better than standard curcumin in reducing colitis disease activity and inflammation, and the results of this study have been published in the journal Science.
In this study, the researchers conducted animal model tests on the effects of two turmeric extracts on colitis, with 95% standard curcumin and BCM-95, respectively. Among them, turmeric extract BCM-95 86% pure curcumin compounds and turmeric oil mixture, the oil mixture also contains 45% of the patented components AR-turmerones.
In the study, all mice were enrolled in standard curcumin or BCM-95 at a dose of 5 mg, 25 mg or 50 mg / kg for more than 1 week. After that, standard curcumin or BCM-95 mice continued to take sodium dextran sulfate (DSS) for about 1 week to induce colitis. Finally, the researchers compared the treatment group and the untreated group with a disease activity index (ADI) to assess the severity of the daily disease.